Olema net loss widens 44.29% to $63.2 million in Q2 FY26

Reuters2026/08/10 20:21

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Olema Pharmaceuticals posted a Q2 net loss of USD 63.2 million, widening from USD 43.8 million a year earlier.
GAAP RD expense rose to USD 57.8 million from USD 43.9 million, on higher clinical development, research, and personnel-related costs.
GAAP GA expense climbed to USD 9.4 million from USD 4 million, driven by higher corporate investment, stock-based compensation, and professional fees.
Cash, cash equivalents, and marketable securities totaled USD 461.1 million at June 30, 2026.
Completed OPERA-01 Phase 3 enrollment; top-line data expected in Q1 2027, with a Bayer collaboration set to start OP-3136-plus-darolutamide enrollment in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Olema Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-342334), on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Olema net loss widens 44.29% to $63.2 million in Q2 FY26

You may also like

Crypto prices